{
    "clinical_study": {
        "@rank": "136144", 
        "arm_group": [
            {
                "arm_group_label": "rosiglitazone", 
                "arm_group_type": "Active Comparator", 
                "description": "avandia"
            }, 
            {
                "arm_group_label": "genetic polymorphism", 
                "arm_group_type": "Active Comparator", 
                "description": "avandia CYP2C8 genotype"
            }
        ], 
        "brief_summary": {
            "textblock": "The genotype profile of CYP2C8 was analyzed in a Korean population. Frequency in\n      multi-ethnic population and in vivo functionality of novel null allelic CYP2C8 variant were\n      evaluated."
        }, 
        "brief_title": "Identification of Null Allelic Variant of CYP2C8 In A Korean Population", 
        "completion_date": {
            "#text": "March 2009", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "detailed_description": {
            "textblock": "Whole blood samples from 50 unrelated Korean subjects were genotyped for 3kb of 5' upstream\n      region, all exon-intron boundaries, exons, and UTR regions of CYP2C8 gene by direct\n      sequencing. Genotyping of CYP2C8 has been addressed only for null allelic variant, CYP2C8*11\n      using pyrosequencing in the 447 Koreans, 93 African-Americans, 100 Caucasians, 348 Chineses\n      and 100 Vietnameses. Then, in-vivo single PK study of CYP2C8 probe, rosiglitazone(4mg), was\n      conducted in 7 healthy subjects with CYP2C8*1/*1 and 2 with CY2C8*1/*11."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy volunteer\n\n        Exclusion Criteria:\n\n          -  Medical problems in taking probe drug"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "11", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 6, 2011", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01872780", 
            "org_study_id": "08-101"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "rosiglitazone", 
                    "genetic polymorphism"
                ], 
                "description": "single oral administration of 4mg of rosiglitazone", 
                "intervention_name": "Rosiglitazone", 
                "intervention_type": "Drug", 
                "other_name": "Avandia"
            }, 
            {
                "arm_group_label": [
                    "rosiglitazone", 
                    "genetic polymorphism"
                ], 
                "description": "CYP2C8*11.", 
                "intervention_name": "CYP2C8 genotype", 
                "intervention_type": "Genetic", 
                "other_name": [
                    "avandia", 
                    "CYP2C8 genotype"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Rosiglitazone"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "CYP2C8", 
            "genetic polymorphism", 
            "rosiglitazone", 
            "Korean"
        ], 
        "lastchanged_date": "June 5, 2013", 
        "number_of_arms": "2", 
        "official_title": "The Effect of CYP2C8 E274Q, a Novel 23452 G>T SNP, on the Disposition of Rosiglitazone in Healthy Subjects: The Genetic Polymorphisms of CYP2C8 in a Korean Population", 
        "overall_official": {
            "affiliation": "Inje University", 
            "last_name": "Jae-Gook Shin, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2009", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "0h,0.33h,0.66h,1h,1.5h,2h,3h,4h,6h,8h,12h,24h", 
            "measure": "AUC", 
            "safety_issue": "No", 
            "time_frame": "12hr"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01872780"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Inje University", 
            "investigator_full_name": "Jae-Gook Shin", 
            "investigator_title": "Department of Pharmacology and Pharmacogenomics Research Center", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "0h,0.33h,0.66h,1h,1.5h,2h,3h,4h,6h,8h,12h,24h", 
            "measure": "Cmax", 
            "safety_issue": "No", 
            "time_frame": "12hr"
        }, 
        "source": "Inje University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Inje University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2008", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}